Q-Line BiotechNSE:QLINE -5.15%12 Net Margin % is 8.97% as of Mar. 2025, which is 47% below its 10-year median of 16.92. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 70.13% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Q-Line Biotech's Net Income for the
six
months ended in Mar. 2025 was ₹281 Mil. Q-Line Biotech's Revenue for the
six
months ended in Mar. 2025 was ₹3,138 Mil. Therefore, Q-Line Biotech's net margin for the quarter that ended in Mar. 2025 was 8.97%.
The historical rank and industry rank for Q-Line Biotech's Net Margin % or its related term are showing as below:
NSE:QLINE'
s Net Margin % Range Over the Past 10 Years
Min: 8.97 Med: 16.92 Max: 17.56
Current: 8.97
NSE:QLINE's Net Margin % is ranked better than 70.13% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs NSE:QLINE: 8.97
Q-Line Biotech (NSE:QLINE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Q-Line Biotech Net Margin % Related Terms
Q-Line Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Net Margin % Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Net Margin %
17.56
16.92
8.97
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Net Margin %
17.56
16.92
8.97
NSE:QLINE vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Q-Line Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Net Margin % of 8.97% as of Mar. 2025. Net margin is the ratio of total net income to net sales. View historical data on Q-Line Biotech and its competitors. This is 47% below median its historical median of 16.92. Over the past decade, Q-Line Biotech's Net Margin % has ranged from 8.97 to 17.56. According to the industry distribution chart, Q-Line Biotech ranks #244 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 29.9%.
Is Q-Line Biotech's Net Margin % too high?
Q-Line Biotech's current Net Margin % of 8.97% is 47% below median its 10-year median of 16.92. Over the past 10 years, this metric has ranged from a low of 8.97 to a high of 17.56. The Medical Devices & Instruments industry median Net Margin % is 2.05. Q-Line Biotech's value of 8.97% is 337.6% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #244 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #244 out of 817 companies for Net Margin %. This puts Q-Line Biotech in the upper half of its industry. The industry median Net Margin % is 2.05. Q-Line Biotech's value of 8.97% is 337.6% above this benchmark. Historically, Q-Line Biotech's own Net Margin % has ranged from 8.97 to 17.56 over the past decade. While the company's 10-year median is 16.92 vs. the industry median of 2.05, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.05, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Net Margin % of 8.97% is 337.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Net Margin % is 8.97%, which is 47% below median its own 10-year median of 16.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Net Margin % of 8.97%. The current Net Margin % is 8.97%, which is 47% below median its 10-year median of 16.92 and 337.6% above the Medical Devices & Instruments industry median of 2.05. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Net Margin % is 8.97% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 